Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Bessemer Group Inc.

Bessemer Group Inc. increased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 861,152.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,280,425 shares of the company’s stock after acquiring an additional 4,279,928 shares during the period. Bessemer Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $133,592,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of TEVA. Allworth Financial LP lifted its stake in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust lifted its stake in Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after acquiring an additional 750 shares in the last quarter. Rothschild Investment LLC lifted its stake in Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after acquiring an additional 1,348 shares in the last quarter. JFS Wealth Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after acquiring an additional 2,000 shares in the last quarter. Finally, LRI Investments LLC lifted its stake in Teva Pharmaceutical Industries by 246.0% during the 3rd quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock worth $57,000 after acquiring an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Truist Financial increased their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. UBS Group increased their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Finally, Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Trading Down 2.9%

TEVA opened at $34.29 on Friday. Teva Pharmaceutical Industries Ltd. has a one year low of $14.99 and a one year high of $37.35. The company has a market cap of $39.42 billion, a P/E ratio of 25.78, a PEG ratio of 3.41 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The business’s 50-day simple moving average is $31.54 and its 200-day simple moving average is $30.42.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion for the quarter. As a group, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total transaction of $750,619.98. Following the transaction, the executive vice president owned 63,647 shares in the company, valued at $2,247,375.57. This trade represents a 25.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Richard D. Francis sold 442,935 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $32.36, for a total value of $14,333,376.60. Following the transaction, the chief executive officer owned 642,099 shares in the company, valued at $20,778,323.64. This represents a 40.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 1,127,018 shares of company stock worth $37,298,712. 0.54% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.